2024-518833-27-00CompletedPhase 1
A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 May 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 11 Nov 2024
- Start date
- 10 Jan 2025
- Lead sponsor
- Quralis Corp.
- EU CT number
- 2024-518833-27-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 24
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharma Bio-Research Group | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.